{"mainPropery":{"diseaseId":9890,"diseaseName":"Optic atrophy 1","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9890/optic-atrophy-1","synonyms":["OPA1","Optic atrophy, juvenile","Kjer-type optic atrophy","Optic atrophy, Kjer type","OAK","Optic atrophy type 1","Autosomal dominant optic atrophy, classic form"],"synonyms-with-source":[{"name":"OPA1"},{"name":"Optic atrophy, juvenile"},{"name":"Kjer-type optic atrophy"},{"name":"Optic atrophy, Kjer type"},{"name":"OAK"},{"name":"Optic atrophy type 1","source":"Genetics Home Reference"},{"name":"Autosomal dominant optic atrophy, classic form","source":"Orphanet"}],"identifiers":[{"identifierType":"OMIM","identifierId":"165500"},{"identifierType":"ORPHANET","identifierId":"98673"},{"identifierType":"UMLS","identifierId":"C0338508"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":9,"diseaseTypeName":"Eye diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"}],"organizations":[{"resourceID":109,"resourceName":"Prevent Blindness America","abbreviation":"","address1":"211 West Wacker Drive, Suite 1700","address2":"","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60606 ","country":"United States","phone":"","tty":"","tollFree":"800-331-2020","fax":"","email":"info@preventblindness.org","url":"http://www.preventblindness.org/","freeText":""},{"resourceID":110,"resourceName":"National Alliance for Eye and Vision Research ","abbreviation":"NAEVR","address1":"1801 Rockville Pike, Suite 400","address2":"","address3":"","address4":"","address5":"","city":"Rockville","state":"MD","zip":"20852","country":"United States","phone":"+1-240-221-2905","tty":"","tollFree":"","fax":"","email":"jamesj@eyeresearch.org","url":"https://www.eyeresearch.org/","freeText":""},{"resourceID":715,"resourceName":"American Foundation for the Blind","abbreviation":"","address1":"1401 South Clark Street","address2":"Suite 730","address3":"","address4":"","address5":"","city":"Arlington","state":"VA","zip":"22202","country":"United States","phone":"212-502-7600","tty":"","tollFree":"800-232-5463","fax":"","email":"info@aph.org","url":"https://www.afb.org/","freeText":""},{"resourceID":2341,"resourceName":"National Federation of the Blind","abbreviation":"","address1":"200 East Wells Street at Jernigan Place","address2":"","address3":"","address4":"","address5":"","city":"Baltimore","state":"MD","zip":"21230","country":"United States","phone":"410-659-9314","tty":"","tollFree":"","fax":"410-685-5653","email":"pmaurer@nfb.org","url":"http://www.nfb.org/","freeText":""},{"resourceID":3421,"resourceName":"Autosomal Dominant Optic Atrophy Association","abbreviation":"","address1":"94 Bethel Court","address2":"","address3":"","address4":"","address5":"","city":"Port Matilda","state":"PA","zip":"16870","country":"","phone":"570-419-8799","tty":"","tollFree":"","fax":"","email":"lindsey.allen@adoaa.org","url":"http://www.adoaa.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/165500' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=165500' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Optic atrophy 1. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Optic+atrophy+1%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Optic atrophy 1. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/optic-atrophy-type-1' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Optic atrophy 1. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98673' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1248/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:165500' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":3904,"questionText":"What is optic atrophy 1?","answerText":"<strong>Optic atrophy 1</strong>, also known as <strong>optic atrophy type 1</strong> is a disease that affects the <a href=\"https://medlineplus.gov/ency/imagepages/9708.htm\">optic nerve</a>. The optic nerve carries signals from the eye to the brain about what is seen. People with optic atrophy type 1 have an optic nerve that has lost some tissue (<a href=\"https://medlineplus.gov/ency/article/001622.htm\">atrophy</a>). This atrophy causes the optic nerve not to work as well as it should, which affects the vision. Signs and symptoms of optic atrophy type 1 include <a href=\"https://medlineplus.gov/ency/article/003040.htm\">vision loss</a>, difficulty distinguishing colors, and an abnormally pale appearance (pallor) of the optic nerve. The vision loss typically begins at age 4-6 years-old. The disease can occur in people of any ethnicity but seems to be more common in people of Danish descent.[2835] <br />\r\n<br />\r\nOther symptoms of optic atrophy type 1 may include <a href=\"https://medlineplus.gov/ency/article/003291.htm\">sensorineural hearing loss</a>, difficulty coordinating movements (<a href=\"https://medlineplus.gov/ency/article/003198.htm\">ataxia</a>) and muscle disease (<a href=\"https://medlineplus.gov/ency/article/001220.htm\">myopathy</a>). When people have optic atrophy type 1 and signs and symptoms other than vision loss, it is known as <a href=\"https://rarediseases.info.nih.gov/diseases/5243/autosomal-dominant-optic-atrophy-plus-syndrome\">autosomal dominant optic atrophy plus syndrome</a>.[2835] <br />\r\n<br />\r\nOptic atrophy type 1 is caused by a genetic change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. The disease is inherited in an <a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a> manner. Optic atrophy type 1 may be suspected when a person has signs and symptoms of the disease on an exam done by an <a href=\"https://aapos.org/terms/conditions/132\">ophthalmologist</a>. <a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">Genetic testing</a> may be used to confirm the diagnosis. Treatment for optic atrophy type 1 may include vision and hearing aids when necessary.[2835][2834]","dateModified":"2018-05-15T00:00:00"},"basicQuestions":[{"questionId":12820,"questionText":"What are the signs and symptoms of optic atrophy 1?","answerText":"The signs and symptoms of optic atrophy type 1 include changes in vision. People with the disease typically have <a href=\"https://medlineplus.gov/ency/article/003040.htm\">vision loss</a> that begins between 4-6 years-old. The vision loss typically affects both eyes and can cause a person to have a range of vision loss from mild to being legally blind. People with optic atrophy type 1 may experience narrowing of the visual field (tunnel vision).[2835][2834] Vision loss may worsen as people with the disease get older. Optic atrophy type 1 can also cause a change in color vision, making it difficult to distinguish between blue and yellow colors (tritanopia).[2835] <br />\r\n<br />\r\nOther signs and symptoms of optic atrophy type 1 may affect other parts of the body. People who have signs and symptoms other than vision loss have <a href=\"https://rarediseases.info.nih.gov/diseases/5243/autosomal-dominant-optic-atrophy-plus-syndrome\">autosomal dominant optic atrophy plus syndrome</a>. Some people with the disease may have hearing loss that is caused by damage to the nerves in the ears (<a href=\"https://medlineplus.gov/ency/article/003291.htm\">sensorineural hearing loss</a>). In severe cases, the hearing loss may be present from birth (congenital), but in other cases it may not be noticeable until a person undergoes a hearing evaluation. Other signs and symptoms of the disease may include difficulty coordinating movements (<a href=\"https://medlineplus.gov/ency/article/003198.htm\">ataxia</a>) and muscle disease (<a href=\"https://medlineplus.gov/ency/article/001220.htm\">myopathy</a>).[2835] <br />\r\n<br />\r\nThe signs and symptoms of optic atrophy type 1 can vary widely, even among people in the same family. For example, some people may have severe vision loss, hearing loss, and muscle weakness, while other people may only have mild vision loss. This wide variation of signs and symptoms of the disease is called <a href=\"https://ghr.nlm.nih.gov/primer/inheritance/penetranceexpressivity\">variable expressivity</a>. In some cases, people with a genetic change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> may not have any signs of optic atrophy type 1 at all. This is called <a href=\"https://ghr.nlm.nih.gov/primer/inheritance/penetranceexpressivity\">reduced penetrance</a>.[2835][2834]<span>&nbsp; </span><br />","dateModified":"2018-05-15T21:01:00","resourceClassificationName":"Symptoms","references":[{"referenceId":2834,"authors":"","articleTitle":"Optic atrophy type 1","bookWebsiteJournalTitle":"Genetics Home Reference","date":"August 2017","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/optic-atrophy-type-1","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":2835,"authors":"Delettre-Cribaillet C, Hamel CP, and Lenaers G","articleTitle":"Optic Atrophy Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"November 12, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1248/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12821,"questionText":"What causes optic atrophy 1?","answerText":"Optic atrophy type 1 is caused by a change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a><span> </span><a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. This gene provides instructions to the body to make a protein that helps the <a href=\"http://www.mrc-mbu.cam.ac.uk/what-are-mitochondria\">mitochondria</a> function correctly. Mitochondria are the parts of the cell that help the cell produce energy. The protein that is created by the <em>OPA1</em> gene helps the mitochondria maintain a normal shape and structure. Therefore, this protein is important in helping mitochondria create energy for the cells to use. The protein also has a role in the process called programmed cell death (apoptosis).[2834]<br />\r\n<br />\r\nWhen there is a pathogenic variant in the <em>OPA1</em> gene, there is not enough functioning protein to help the mitochondria maintain the normal shape and structure. This causes the mitochondria to not produce enough energy for cells. It also causes cells to undergo cell death earlier than they should. When cells of the eyes do not receive enough energy and undergo cell death earlier than they should, it causes loss of tissue in parts of the eye called the <a href=\"https://medlineplus.gov/ency/article/002291.htm\">retina</a> and the <a href=\"https://medlineplus.gov/ency/imagepages/9708.htm\">optic nerve</a>. These parts of the eye transmit signals from the eyes to the brain so that we can see. Loss of cells in the retina and optic nerve cause the signs and symptoms of optic atrophy type 1.[2834] <br />\r\n<br />\r\nIn some cases, people with optic atrophy type 1 do not have a pathogenic variant in the <em>OPA1</em> gene that is found on <a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">genetic testing</a>. In these cases, the exact cause of the disease is unknown.[14636]","dateModified":"2018-05-15T21:05:00","resourceClassificationName":"Cause","references":[{"referenceId":2834,"authors":"","articleTitle":"Optic atrophy type 1","bookWebsiteJournalTitle":"Genetics Home Reference","date":"August 2017","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/optic-atrophy-type-1","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14636,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy, classic form","bookWebsiteJournalTitle":"Orphanet","date":"August 2015","volume":"","pages":"","url":"https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98673","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12822,"questionText":"How is optic atrophy 1 inherited?","answerText":"Optic atrophy type 1 is inherited in an <a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a> manner.[2835] This means that having a genetic change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in one copy of the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> can cause the signs and symptoms of optic atrophy type 1. We inherit one copy of the <em>OPA1</em> gene from our mother and the other from our father. When a person with a pathogenic variant in <em>OPA1</em> has children, for each child there is a:<br />\r\n<ul style=\"list-style-type: disc;\">\r\n    <li>50% chance to inherit the changed copy of <em>OPA1</em></li>\r\n    <li>50% chance to inherit the working copy of <em>OPA1</em></li>\r\n</ul>\r\nWhen a person has a pathogenic variant in the <em>OPA1</em> gene, it can be difficult to predict the signs and symptoms that the person may have. This is because the signs and symptoms of optic atrophy type 1 can vary, even among members of the same family (<a href=\"https://ghr.nlm.nih.gov/primer/inheritance/penetranceexpressivity\">variable expressivity</a>). In addition, some people with pathogenic variants in <em>OPA1</em> do not have any signs or symptoms of optic atrophy type 1 at all (<a href=\"https://ghr.nlm.nih.gov/primer/inheritance/penetranceexpressivity\">reduced penetrance</a>).[2835] <br />\r\n<br />\r\nIn most cases, people with optic atrophy type 1 inherit the pathogenic variant in <em>OPA1</em> from one of their parents. This parent may have different signs and symptoms of the disease than other family members, or the parent may not have any signs or symptoms of the disease at all.[2835] It is not known why there is such a wide variation of signs and symptoms that can be associated with optic atrophy type 1. It may be that there are genetic and environmental factors that influence the signs and symptoms of the disease.[2836]<br />\r\n<br />\r\nIn some cases, a pathogenic variant in the <em>OPA1</em> gene occurs for the first time in the person diagnosed with optic atrophy type 1, and it was not inherited from either parent. Pathogenic variants that are occurring for the first time are called <em>de novo</em>.[2835]<br />\r\n<br />\r\nPeople who have questions about the chances for other family members to have optic atrophy type 1 may wish to speak with a genetic counselor.<br />\r\n<br />\r\n<br />","dateModified":"2018-05-15T21:08:00","resourceClassificationName":"Inheritance","references":[{"referenceId":2836,"authors":"Yu-Wai-Man P, et al","articleTitle":"Multi-system neurological disease is common in patients with OPA1 mutations","bookWebsiteJournalTitle":"Brain","date":"March 2010","volume":"133(Pt 3)","pages":"771-786","url":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842512/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12823,"questionText":"How is optic atrophy 1 diagnosed?","answerText":"Optic atrophy type 1 may be suspected when a person has signs and symptoms of the disease including <a href=\"https://medlineplus.gov/ency/article/003040.htm\">vision loss</a> beginning in childhood, loss of color vision affecting blue and yellow colors (tritanopia), and findings of loss of tissue of the <a href=\"https://medlineplus.gov/ency/imagepages/9708.htm\">optic nerve</a> (<a href=\"https://medlineplus.gov/ency/article/001622.htm\">optic atrophy</a>) on an exam by an <a href=\"https://aapos.org/terms/conditions/132\">ophthalmologist</a>. A doctor may take a medical history and family history, as people with optic atrophy type 1 may have other signs and symptoms of the disease or other family members with signs and symptoms. The diagnosis can be confirmed with <a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">genetic testing</a> of the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>.[2835]","dateModified":"2018-05-15T21:11:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":2835,"authors":"Delettre-Cribaillet C, Hamel CP, and Lenaers G","articleTitle":"Optic Atrophy Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"November 12, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1248/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12824,"questionText":"How might optic atrophy 1 be treated?","answerText":"Treatment for optic atrophy type 1 typically includes regular exams by an <a href=\"https://aapos.org/terms/conditions/132\">ophthalmologist</a>, including measuring vision and color vision, and regular evaluation by an <a href=\"https://www.asha.org/Students/Audiology/\">audiologist</a>. Vision aids such as glasses, contact lenses, and magnifiers may be used to help treat vision loss. <a href=\"https://medlineplus.gov/cochlearimplants.html\">Cochlear implants</a> may help improve hearing in people who have <a href=\"https://medlineplus.gov/ency/article/003291.htm\">sensorineural hearing loss</a>.[2835] Some people with optic atrophy type 1 have shown improvement in vision after being treated with idebenone. However, more research is needed to determine how effective this medication is in treating the disease.[14636][7018]<br />\r\n<br />\r\nPeople with optic atrophy type 1 may be recommended to avoid alcohol intake and certain medications, as these can impact the function of <a href=\"http://www.mrc-mbu.cam.ac.uk/what-are-mitochondria\">mitochondria</a> in the cells.[2835]<br />","dateModified":"2018-05-15T21:13:00","resourceClassificationName":"Treatment","references":[{"referenceId":2835,"authors":"Delettre-Cribaillet C, Hamel CP, and Lenaers G","articleTitle":"Optic Atrophy Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"November 12, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1248/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":7018,"authors":"Barboni P. et al","articleTitle":"Idebenone treatment in patients with OPA1-mutant dominant optic atrophy","bookWebsiteJournalTitle":"Brain","date":"February 2013","volume":"136(Pt 2)","pages":"e231","url":"https://www.ncbi.nlm.nih.gov/pubmed/23388408","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14636,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy, classic form","bookWebsiteJournalTitle":"Orphanet","date":"August 2015","volume":"","pages":"","url":"https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98673","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":3905,"questionText":"What is the long-term outlook for people with optic atrophy 1?","answerText":"In general, people with optic atrophy type 1 have worsening <a href=\"https://medlineplus.gov/ency/article/003040.htm\">vision loss</a> over time. However, some people only have mild vision loss, and for some people the vision loss does not worsen with time. Vision loss can interfere with daily life, but it is not expected to shorten a person&rsquo;s lifespan.[2836]<br />\r\n<br />\r\nThe long-term outlook for people with optic atrophy type 1 may depend on the severity of vision loss and if there are any other symptoms, such as hearing loss or muscle weakness. About 20% of people with a genetic change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> have symptoms other than vision loss.[2836] <br />\r\n<br />\r\nIn some cases, people with optic atrophy type 1 may experience anxiety and depression due to the symptoms of the disease.[2836] It is important to contact your doctor if you have concerns that you or a family member is suffering from <a href=\"https://medlineplus.gov/anxiety.html\">anxiety</a> or <a href=\"https://medlineplus.gov/depression.html\">depression</a>.","dateModified":"2018-05-15T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":2836,"authors":"Yu-Wai-Man P, et al","articleTitle":"Multi-system neurological disease is common in patients with OPA1 mutations","bookWebsiteJournalTitle":"Brain","date":"March 2010","volume":"133(Pt 3)","pages":"771-786","url":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842512/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":11972,"relatedDiseaseName":"Dominant optic atrophy","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":28892,"abbreviatedInquiry":"What is the life expectancy for individuals with optic atrophy 1?","caseQuestions":[{"questionId":3904,"questionText":"What is optic atrophy 1?","answerText":"<strong>Optic atrophy 1</strong>, also known as <strong>optic atrophy type 1</strong> is a disease that affects the <a href=\"https://medlineplus.gov/ency/imagepages/9708.htm\">optic nerve</a>. The optic nerve carries signals from the eye to the brain about what is seen. People with optic atrophy type 1 have an optic nerve that has lost some tissue (<a href=\"https://medlineplus.gov/ency/article/001622.htm\">atrophy</a>). This atrophy causes the optic nerve not to work as well as it should, which affects the vision. Signs and symptoms of optic atrophy type 1 include <a href=\"https://medlineplus.gov/ency/article/003040.htm\">vision loss</a>, difficulty distinguishing colors, and an abnormally pale appearance (pallor) of the optic nerve. The vision loss typically begins at age 4-6 years-old. The disease can occur in people of any ethnicity but seems to be more common in people of Danish descent.[2835] <br />\r\n<br />\r\nOther symptoms of optic atrophy type 1 may include <a href=\"https://medlineplus.gov/ency/article/003291.htm\">sensorineural hearing loss</a>, difficulty coordinating movements (<a href=\"https://medlineplus.gov/ency/article/003198.htm\">ataxia</a>) and muscle disease (<a href=\"https://medlineplus.gov/ency/article/001220.htm\">myopathy</a>). When people have optic atrophy type 1 and signs and symptoms other than vision loss, it is known as <a href=\"https://rarediseases.info.nih.gov/diseases/5243/autosomal-dominant-optic-atrophy-plus-syndrome\">autosomal dominant optic atrophy plus syndrome</a>.[2835] <br />\r\n<br />\r\nOptic atrophy type 1 is caused by a genetic change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. The disease is inherited in an <a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a> manner. Optic atrophy type 1 may be suspected when a person has signs and symptoms of the disease on an exam done by an <a href=\"https://aapos.org/terms/conditions/132\">ophthalmologist</a>. <a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">Genetic testing</a> may be used to confirm the diagnosis. Treatment for optic atrophy type 1 may include vision and hearing aids when necessary.[2835][2834]","dateModified":"2018-05-15T00:00:00","references":[{"referenceId":2834,"authors":"","articleTitle":"Optic atrophy type 1","bookWebsiteJournalTitle":"Genetics Home Reference","date":"August 2017","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/optic-atrophy-type-1","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":2835,"authors":"Delettre-Cribaillet C, Hamel CP, and Lenaers G","articleTitle":"Optic Atrophy Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"November 12, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1248/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":3905,"questionText":"What is the long-term outlook for people with optic atrophy 1?","answerText":"In general, people with optic atrophy type 1 have worsening <a href=\"https://medlineplus.gov/ency/article/003040.htm\">vision loss</a> over time. However, some people only have mild vision loss, and for some people the vision loss does not worsen with time. Vision loss can interfere with daily life, but it is not expected to shorten a person&rsquo;s lifespan.[2836]<br />\r\n<br />\r\nThe long-term outlook for people with optic atrophy type 1 may depend on the severity of vision loss and if there are any other symptoms, such as hearing loss or muscle weakness. About 20% of people with a genetic change (pathogenic variant or <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> have symptoms other than vision loss.[2836] <br />\r\n<br />\r\nIn some cases, people with optic atrophy type 1 may experience anxiety and depression due to the symptoms of the disease.[2836] It is important to contact your doctor if you have concerns that you or a family member is suffering from <a href=\"https://medlineplus.gov/anxiety.html\">anxiety</a> or <a href=\"https://medlineplus.gov/depression.html\">depression</a>.","dateModified":"2018-05-15T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":2836,"authors":"Yu-Wai-Man P, et al","articleTitle":"Multi-system neurological disease is common in patients with OPA1 mutations","bookWebsiteJournalTitle":"Brain","date":"March 2010","volume":"133(Pt 3)","pages":"771-786","url":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842512/","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9141,"phenoTypeName":"Color vision defect","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14706,"phenoTypeName":"Moderately reduced visual acuity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":1293,"phenoTypeName":"Morning glory anomaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9185,"phenoTypeName":"Ophthalmoplegia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4518,"phenoTypeName":"Sensorimotor neuropathy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11337,"phenoTypeName":"Sensorineural hearing impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15278,"phenoTypeName":"Temporal optic disc pallor","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9186,"phenoTypeName":"Central scotoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14500,"phenoTypeName":"Myopathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5615,"phenoTypeName":"Ptosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14305,"phenoTypeName":"Abnormality of the periventricular white matter","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8737,"phenoTypeName":"Areflexia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13687,"phenoTypeName":"Atrophy/Degeneration affecting the brainstem","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13817,"phenoTypeName":"Basal ganglia calcification","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5624,"phenoTypeName":"Cataract","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8731,"phenoTypeName":"Cerebellar atrophy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13693,"phenoTypeName":"Corpus callosum atrophy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14182,"phenoTypeName":"Diabetes mellitus","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":7204,"phenoTypeName":"Duane anomaly","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13402,"phenoTypeName":"Dysphagia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13239,"phenoTypeName":"Feeding difficulties","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14131,"phenoTypeName":"Hallucinations","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8728,"phenoTypeName":"Hemiparesis","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":10140,"phenoTypeName":"Horizontal nystagmus","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":9728,"phenoTypeName":"Hypogonadism","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14184,"phenoTypeName":"Hypothyroidism","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13074,"phenoTypeName":"Macrocytic anemia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13709,"phenoTypeName":"Migraine","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":3980,"phenoTypeName":"Myalgia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":10109,"phenoTypeName":"Nystagmus","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":3896,"phenoTypeName":"Pes cavus","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":9175,"phenoTypeName":"Progressive external ophthalmoplegia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5281,"phenoTypeName":"Proximal muscle weakness","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5270,"phenoTypeName":"Scapular winging","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14505,"phenoTypeName":"Skeletal muscle atrophy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8712,"phenoTypeName":"Spastic paraplegia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":10498,"phenoTypeName":"Strabismus","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":12560,"phenoTypeName":"Weakness of facial musculature","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":9191,"phenoTypeName":"Abnormal amplitude of pattern reversal visual evoked potentials","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":9166,"phenoTypeName":"Centrocecal scotoma","percentRanges":"-"},{"phenoTypeId":7386,"phenoTypeName":"Incomplete penetrance","percentRanges":"-"},{"phenoTypeId":6244,"phenoTypeName":"Insidious onset","percentRanges":"-"},{"phenoTypeId":8266,"phenoTypeName":"Pallor","percentRanges":"-"},{"phenoTypeId":10114,"phenoTypeName":"Red-green dyschromatopsia","percentRanges":"-"},{"phenoTypeId":10515,"phenoTypeName":"Reduced visual acuity","percentRanges":"-"},{"phenoTypeId":9142,"phenoTypeName":"Tritanomaly","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Optic_atrophy_1"}